Ms. Jenn Hepburn reports
EMERALD HEALTH THERAPEUTICS CLOSES FINAL TRANCHE PROSPECTUS SALE
Emerald Health Therapeutics Inc. has closed the final tranche of its $3-million prospectus offering, announced in its news release dated Jan. 6, 2020.
Pursuant to this final closing, Emerald has issued an aggregate of 2,748,276 units of Emerald at a price of 29 cents per unit for total gross proceeds of $797,000. The initial tranche of the offering closed on Feb. 6, 2020, for gross proceeds of $2,203,000.
Each unit consists of one common share of Emerald and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share of Emerald at a price of 38.5 cents per warrant share for a period of five years following the closing of the offering.
The company intends to use the net proceeds of the offering for general working capital purposes, including the payment of salaries, consulting fees and operating expenses.
The units were distributed pursuant to a shelf prospectus supplement filed in all of the provinces of Canada pursuant to National Instrument 44-102 (Shelf Distributions).
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics is committed to creating new consumer experiences with recreational and wellness-oriented cannabis products. With an emphasis on innovation and production excellence, Emerald has built a platform of distinct operating assets designed to uniquely serve the Canadian marketplace and international opportunities.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.